Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet talked with Proactive's Stephen Gunnion about the granting of approval for Grassmuno, its grass allergy immunotherapy vaccine, in Germany - a significant milestone for the company.
Llobet explained that the product is the first to be approved under the Therapieallergene-Verordnung (TAV) framework in the SCIT (subcutaneous immunotherapy) segment. The vaccine targets moderate to severe grass allergy sufferers, which he said represents the largest segment of the allergy market. "It's been a long journey, about one decade… tens of millions of investment to produce a state-of-the-art product," Llobet noted.
He highlighted key advantages of the product: it is aluminium-free, adjuvanted, and designed as a short-course treatment — improving patient compliance and convenience. Allergy Therapeutics plans to replace its previous Pollinex Quattro Grass product in Germany with this new version, which has a higher concentration of active ingredients.
Next steps include market expansion in Europe, Asia, and the US, leveraging clinical trials already coordinated with the FDA. The company is also exploring mutual recognition across EU territories via the Paul-Ehrlich-Institut.
Llobet also touched on recent financials, pointing to portfolio restructuring and the shift from NPP products to registered treatments. Additionally, he discussed a potential dual primary listing in Hong Kong, aiming to engage Chinese investors and support expansion in the Asian market.
Visit Proactive’s YouTube channel for more company interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications to stay updated.
#AllergyTherapeutics #GrassAllergy #Immunotherapy #SCIT #BiotechNews #VaccineApproval #HealthInnovation #EuropeanHealthcare #FDA #HongKongListing #ClinicalTrials #AllergyVaccine #PharmaUpdates #InvestingInBiotech #ProactiveInvestors